Idogen aims to develop the company’s first two projects until clinical effect has been demonstrated and then enter into agreements on continued development and marketing together with major partners. As a strategic alternative, the company can develop the first project, IDO 8, to the market without partner.

Quotes for Idogen AB

Right Now

+/-
0
%
0,00%
Latest
0.6
High
0.618
Low
0.6
Volume
23 750
Turnover (SEK)
14 340
Value (MSEK)
29,1

Board

CEO

  • Lars Hedbys

Chairman Of The Board

  • Agneta Edberg

Board

  • Agneta Edberg
  • Leif G Salford
  • Karin Hoogendoorn
  • Christina Herder

Videos

Largest Owners

Name Capital % Votes % Date
Danica Pension 11,89 11,89 2019-01-09
HCN Group AB 4,53 4,53 2019-01-11
Leif G Salford 3,37 3,37 2018-12-05
Avanza Pension 2,12 2,12 2018-12-31
Ventac Holding (Cyprus) Ltd 1,57 1,57 2018-12-31
Nils Berntsson 1,45 1,45 2018-12-31
Olov Sjögren 1,40 1,40 2018-12-31
Charlotte Widing 0,78 0,78 2018-12-31
Mikael Lönn 0,73 0,73 2018-12-31
Henrik Magne Wilhelm Widegren 0,61 0,61 2018-12-31
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Inquiry Financial

Upcoming reports

  • 2019-05-28 Delårsrapport Q1

  • 2019-08-20 Halvårsrapport

  • 2019-10-22 Delårsrapport Q3

  • 2020-02-11 Bokslutskommuniké